Enriching the Study Population for Ischemic Stroke Therapeutic Trials Using a Machine Learning Algorithm.
Source check: Source checked. Not independent scientific confirmation.
Finding: Gradient boosting identified ischemic-stroke patients likely to have a future event in a trial-relevant time window, evaluating cohort enrichment on linked health records. Organization is unavailable in the deposited bibliographic metadata.
Technology: Gradient-boosting model for stroke cohort enrichment
Publication: Publication status unspecified in annotation · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Methods train gradient boosting to predict ischemic stroke within one year; Results assess selection/enrichment performance in a large claims dataset.
- Test and result
- Gradient boosting identified ischemic-stroke patients likely to have a future event in a trial-relevant time window, evaluating cohort enrichment on linked health records.
- Limitation / still unknown
- The reviewed study does not establish validation or benefit beyond its reported evaluation.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8823366/
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.